14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
JBIO vs EDIT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Jade Biosciences, Inc. (JBIO) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (32.6/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. JBIO trades at $15.34 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).
Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. JBIO 32.6/100 SELL), JBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
Technical & Structure Timing Caution: JBIO is currently in a Breakdown options structure phase (RSI 51.0); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JBIO vs EDIT. Trailing 12-month operating profitability (JBIO 0.0% vs EDIT -167.0%) and valuation multiples (JBIO N/M vs EDIT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
EDIT Moat ProfileConcentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published · CRISPR / Gene Editing
Investor FAQ JBIO vs EDIT Key Questions & Quantitative Answers
As of Nov 16, 2026, Jade Biosciences, Inc. (JBIO) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (32.6/100 SELL vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality, Options & Positioning), while EDIT wins 4–2 across the 6-pillar growth and valuation breakdown. JBIO trades at $15.34 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. JBIO 32.6/100 SELL), JBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: JBIO is currently in a Breakdown options structure phase (RSI 51.0); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EDIT leads the Growth & Scale pillar: JBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). On trailing 12-month operating scale, JBIO generates N/A in USD-normalized revenue versus $50M for EDIT. In operating R&D and SG&A reinvestment, JBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.
EDIT screens cheaper on headline valuation multiples. JBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JBIO (-89.2% ROE) versus EDIT (-147.4% ROE) capital efficiency.
In options market volatility and institutional positioning, JBIO carries 73.0% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.35β · 60% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.